Microsoft Word - Candidates for 2017 ERP of the Year

54

data that exists in support of this method's applicability to the SMPR 2014.012 or 2014.010.

Covance, Song)

PDE5-004

Title: Testing for Phosphodiesterase Type 5 (PDE5) Inhibitors in Dietary Supplements

Motion 1: MOTION to not move PDE5-004 to First Action Official Methods SM status. Motion 2: MOTION that ERP finds this method valuable for screening and would like to see a further submission of data demonstrating applicability towards the SMPR 2014.012. Motion 1: MOTION to move PDE5-005 to First Action Official Methods SM status. Motion 2 : MOTION to be considered for Final Action Official Methods SM status, the method author(s) should: 1. Provide reproducibility data 2. Break out AOAC SMPR 2014.011: -Matrix match spike recovery -Recovery options 3. Beak out AOAC SMPR 2014.012 and AOAC SMPR 2014.010.

Motion 1: Phillips/Sullivan, 7/0/1 (Abstain: Covance) Motion 2: Phillips/Spzylka, 7/0/1 (Abstain: Covance) Motion 1: Phillips/Koerner, 5/0/2 (Mastovska , Sullivan) Motion 2: Phillips/Spzylka, 5/0/2 (Mastovska , Sullivan)

Primary: Jerry Zweigenbaum

Submitter: Said Goueli, Promega

Secondary: Teresa Cain

Note: This method was supplemented with a presentation from the method author. Title: SLV Study of a Method for Screening Submitter: Katerina Mastovska, Covance

PDE5-005

Primary: Teresa Cain Secondary: Tom Phillips

-Feedback from other users and a mechanism to receive that feedback.

03/12/2018